✦ LIBER ✦

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

✍ Scribed by Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko; Ishiguro, Naoki; Ryu, Junnosuke; Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Fujii, Koichi; Yoshinaga, Takunari; Freundlich, Bruce; Suzukawa, Michio

Book ID: 113028854
Publisher: Springer
Year: 2011
Tongue: English
Weight: 272 KB
Volume: 32
Category: Article
ISSN: 0172-8172
DOI: 10.1007/s00296-011-1807-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Postmarketing surveillance of safety and

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis

✍ Takao Koike; Masayoshi Harigai; Shigeko Inokuma; Naoki Ishiguro; Junnosuke Ryu; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 238 KB

Switching from infliximab to once-weekly

Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four–week study

✍ Cantini, Fabrizio ;Niccoli, Laura ;Benucci, Maurizio ;Chindamo, Daniela ;Nannini 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 2 views

Impact of trough serum level on radiogra

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

✍ Tsutomu Takeuchi; Nobuyuki Miyasaka; Kazuhiko Inoue; Tohru Abe; Takao Koike 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 307 KB

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Outcomes after switching from one anti–t

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

✍ Kimme L. Hyrich; Mark Lunt; Kath D. Watson; Deborah P. M. Symmons; Alan J. Silma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The pres

Efficacy and safety of etanercept 50 mg

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug–controlled study

✍ Michael E. Weinblatt; Michael H. Schiff; Eric M. Ruderman; Clifton O. Bingham II 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 3 views